AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has launched a Phase III clinical trial titled Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) to assess the safety and efficacy of Anifrolumab in treating systemic sclerosis. This study aims to provide a new therapeutic option for patients with this rare autoimmune disease, which currently has limited treatment options.
Anifrolumab, the intervention being tested, is administered subcutaneously and is designed to modulate the immune response in patients with systemic sclerosis. The study will compare Anifrolumab to a placebo to evaluate its effectiveness.
The study is a multicenter, randomized, double-blind, placebo-controlled trial with a parallel assignment. Participants are randomly allocated to receive either Anifrolumab or a placebo for 52 weeks, followed by an open-label period where all participants receive Anifrolumab. The primary purpose is to treat systemic sclerosis effectively.
The study began on November 8, 2023, with an expected primary completion date in 2025. The last update was submitted on July 14, 2025. These timelines are crucial for investors tracking the progress and potential market entry of Anifrolumab.
This clinical update could positively impact AstraZeneca’s stock performance by enhancing investor confidence in the company’s pipeline. The successful development of Anifrolumab could position AstraZeneca as a leader in the systemic sclerosis treatment market, potentially affecting competitors in the autoimmune disease sector.
The DAISY study is ongoing, with further details available on the ClinicalTrials portal.